8 studies found for:    hurthle
Show Display Options
Rank Status Study
1 Active, not recruiting Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Drug: Temsirolimus and Sorafenib
2 Completed Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
Conditions: Malignant Struma Ovarii;   Papillary Thyroid Cancer;   Hurthle Cell Thyroid Cancer;   Follicular Thyroid Cancer;   Tall Cell Variant Thyroid Cancer
Intervention:
3 Completed
Has Results
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
Conditions: Recurrent Thyroid Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Papillary Thyroid Cancer
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
4 Completed A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
Conditions: Papillary Thyroid Cancer;   Follicular Thyroid Cancer;   Huerthle Cell Thyroid Cancer;   Renal Cell Carcinoma
Interventions: Drug: rosiglitazone;   Drug: XL184
5 Active, not recruiting
Has Results
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Condition: Thyroid Neoplasms
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Placebo
6 Completed A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Drug: AMG 706
7 Recruiting IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Condition: Thyroid Cancer
Intervention: Radiation: I131 1.1 GBq
8 Recruiting Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
Condition: Thyroid Cancer
Intervention: Drug: Sorafenib

Indicates status has not been verified in more than two years